Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNC003
MIFTS: 57

Bone Cancer

Categories: Bone diseases, Cancer diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bone Cancer

About this section

MalaCards integrated aliases for Bone Cancer:

Name: Bone Cancer 12 42 15
Malignant Bone Neoplasm 12 17 71
Bone Carcinoma 12 15 71
Bone Neoplasms 74 43 71
Bone Neoplasm 12 17
Malignant Neoplasm of Bone 12
Malignant Osseous Tumor 12
Malignant Bone Tumour 12
Osteosarcoma of Bone 71
Osteogenic Neoplasm 71
Ca - Bone Cancer 12
Neoplasm of Bone 12
Osseous Tumor 12
Bone Tumour 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:184 DOID:2762
MeSH 43 D001859
NCIt 49 C36082 C9343
UMLS 71 C0005967 C0279530 C0585442 more
Sources

Summaries for Bone Cancer

About this section
MedlinePlus : 42 Cancer that starts in a bone is uncommon. Cancer that has spread to the bone from another part of the body is more common. There are three types of bone cancer: Osteosarcoma - occurs most often between ages 10 and 19. It is more common in the knee and upper arm. Chondrosarcoma - starts in cartilage, usually after age 40 Ewing's sarcoma - occurs most often in children and teens under 19. It is more common in boys than girls. The most common symptom of bone cancer is pain. Other symptoms vary, depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy, and radiation therapy. Because bone cancer can come back after treatment, regular follow-up visits are important. NIH: National Cancer Institute

MalaCards based summary : Bone Cancer, also known as malignant bone neoplasm, is related to bone marrow cancer and osteogenic sarcoma, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Bone Cancer is TNFSF11 (TNF Superfamily Member 11), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Akt Signaling. The drugs Dopamine and Methamphetamine have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate, and related phenotypes are growth/size/body region and behavior/neurological

Disease Ontology : 12 A connective tissue cancer that is located in bone and is characterized by uncontrolled cellular proliferation that destroys normal bone tissue.

Wikipedia : 74 A bone tumor is a neoplastic growth of tissue in bone. Abnormal growths found in the bone can be either... more...

Sources

Related Diseases for Bone Cancer

About this section

Diseases in the Bone Cancer family:

Primary Bone Cancer

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 473)
# Related Disease Score Top Affiliating Genes
1 bone marrow cancer 33.2 TP53 TNFSF11 MIR140 IL6
2 osteogenic sarcoma 33.2 TP53 TNFSF11 MIR140 IL6 CYCS CDKN2A
3 bone squamous cell carcinoma 32.9 TP53 RLN2 MMP9 EGFR CDKN2A
4 li-fraumeni syndrome 32.8 TP53 ESR1 EGFR CDKN2A
5 keratocystic odontogenic tumor 31.3 TP53 TNFSF11 MMP9
6 pain agnosia 31.1 TRPV1 PENK PDYN IL6 CNR1
7 osteomyelitis 31.0 TNFSF11 IL6 CCL2 BMP2
8 bone disease 31.0 TNFSF11 TNFRSF11A MMP9 IL6 ESR1 COL1A1
9 bone resorption disease 31.0 TNFSF11 TNFRSF11A MIR140 IL6 ESR1 COL1A1
10 giant cell tumor 30.9 TNFSF11 TNFRSF11A MMP9
11 chordoma 30.9 TP53 MTAP MIR140 EGFR CDKN2A
12 villonodular synovitis 30.6 TNFSF11 MMP9
13 fasciitis 30.6 TP53 IL6 ESR1
14 neurofibroma 30.6 TP53 EGFR CDKN2A
15 pigmented villonodular synovitis 30.5 TP53 TNFSF11 MMP9
16 histiocytoma 30.5 TP53 MTAP CDKN2A
17 osteonecrosis 30.5 TNFSF11 ESR1 BMP2
18 meningioma, familial 30.5 TP53 MMP9 ESR1 EGFR CDKN2A
19 radiculopathy 30.4 PENK IL6 CCL2 BMP2
20 bone inflammation disease 30.4 TNFSF11 MMP9 MIR140 IL6 CCL2
21 mammary paget's disease 30.4 TNFSF11 TNFRSF11A ESR1 EGFR
22 peripheral nervous system disease 30.3 TRPV1 IL6 CYCS CCL2
23 ameloblastoma 30.3 TP53 TNFSF11 MMP9
24 oral cancer 30.3 TP53 MMP9 EGFR CDKN2A
25 estrogen-receptor positive breast cancer 30.3 TP53 ESR1 EGFR
26 dermatofibrosarcoma protuberans 30.3 TP53 COL1A1 CDKN2A
27 connective tissue cancer 30.2 TP53 MIR140 IL6 EGFR CDKN2A
28 breast adenocarcinoma 30.2 TP53 TNFSF11 MMP9 ESR1 EGFR CYCS
29 pheochromocytoma 30.2 PENK PDYN IL6 CYCS CDKN2A
30 myeloma, multiple 30.2 TP53 TNFSF11 MMP9 MIR140 IL6 ESR1
31 neuroblastoma 30.2 TP53 MMP9 IL6 ESR1 EGFR CYCS
32 nasopharyngeal carcinoma 30.1 TP53 MMP9 IL6 EGFR CYCS CDKN2A
33 glioblastoma multiforme 30.1 TP53 MMP9 IL6 ESR1 EGFR CDKN2A
34 osteoporosis 29.8 TRPV1 TP53 TNFSF11 TNFRSF11A MMP9 MIR140
35 prostate cancer 29.7 TP53 TNFSF11 TNFRSF11A MMP9 IL6 ESR1
36 ovarian cancer 29.7 TP53 MMP9 MIR140 IL6 ESR1 EGFR
37 chest wall bone cancer 12.3
38 primary bone cancer 12.3
39 aneurysmal bone cysts 11.3
40 chondrosarcoma 11.3
41 ewing sarcoma 11.3
42 retinoblastoma 11.2
43 bone giant cell tumor 11.2
44 paget's disease of bone 11.2
45 maxillary cancer 11.1
46 multiple enchondromatosis, maffucci type 11.1
47 enchondromatosis, multiple, ollier type 10.9
48 rapadilino syndrome 10.9
49 rothmund-thomson syndrome, type 2 10.9
50 long bones of lower limb cancer 10.9

Graphical network of the top 20 diseases related to Bone Cancer:



Diseases related to Bone Cancer
Sources

Symptoms & Phenotypes for Bone Cancer

About this section

UMLS symptoms related to Bone Cancer:


back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Bone Cancer:

45 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.46 ATF3 BMP2 CDKN2A CNR1 COL1A1 CYCS
2 behavior/neurological MP:0005386 10.45 ATF3 CDKN2A CNR1 COL1A1 CYCS ESR1
3 homeostasis/metabolism MP:0005376 10.41 ATF3 BMP2 CDKN2A CNR1 COL1A1 EGFR
4 immune system MP:0005387 10.4 ATF3 BMP2 CCL2 CDKN2A COL1A1 CYCS
5 cellular MP:0005384 10.37 BMP2 CDKN2A CNR1 COL1A1 CYCS EGFR
6 integument MP:0010771 10.36 ATF3 CDKN2A CNR1 COL1A1 EGFR ESR1
7 cardiovascular system MP:0005385 10.34 BMP2 CDKN2A COL1A1 CYCS EGFR ESR1
8 hematopoietic system MP:0005397 10.33 ATF3 BMP2 CDKN2A COL1A1 CYCS EGFR
9 digestive/alimentary MP:0005381 10.32 BMP2 CDKN2A CNR1 COL1A1 EGFR ESR1
10 endocrine/exocrine gland MP:0005379 10.31 ATF3 CDKN2A COL1A1 CYCS EGFR ESR1
11 mortality/aging MP:0010768 10.3 BMP2 CDKN2A CNR1 COL1A1 CYCS EGFR
12 adipose tissue MP:0005375 10.26 ATF3 CNR1 COL1A1 EGFR ESR1 IL6
13 nervous system MP:0003631 10.18 ATF3 BMP2 CDKN2A CNR1 COL1A1 CYCS
14 neoplasm MP:0002006 10.14 ATF3 CDKN2A COL1A1 EGFR ESR1 IL6
15 craniofacial MP:0005382 10.13 BMP2 COL1A1 CYCS EGFR TNFRSF11A TNFSF11
16 liver/biliary system MP:0005370 10.13 CDKN2A COL1A1 EGFR ESR1 IL6 MTAP
17 limbs/digits/tail MP:0005371 10.1 BMP2 COL1A1 EGFR ESR1 MMP9 TNFRSF11A
18 no phenotypic analysis MP:0003012 10.1 ATF3 CDKN2A CNR1 COL1A1 EGFR ESR1
19 muscle MP:0005369 10.03 CDKN2A COL1A1 EGFR ESR1 IL6 MMP9
20 reproductive system MP:0005389 10.03 BMP2 CDKN2A CNR1 COL1A1 EGFR ESR1
21 respiratory system MP:0005388 9.9 ATF3 CDKN2A COL1A1 EGFR ESR1 IL6
22 skeleton MP:0005390 9.8 ATF3 BMP2 CDKN2A CNR1 COL1A1 CYCS
23 vision/eye MP:0005391 9.28 ATF3 CDKN2A COL1A1 EGFR IL6 MMP9
Sources

Drugs & Therapeutics for Bone Cancer

About this section

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 239)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
3
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
4
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
5
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
6 Sympathomimetics Phase 4
7 Dopamine Agents Phase 4
8 Dopamine Uptake Inhibitors Phase 4
9 Adrenergic Agents Phase 4
10 Vitamins Phase 4
11 Calciferol Phase 4
12 Immunoglobulin G Phase 4
13 Analgesics Phase 4
14 Hormones Phase 4
15 Psychotropic Drugs Phase 4
16 Tranquilizing Agents Phase 4
17 Anti-Anxiety Agents Phase 4
18 Calcium, Dietary Phase 4
19 calcium channel blockers Phase 4
20 Anticonvulsants Phase 4
21 sodium fluoride Approved Phase 3 7681-49-4
22
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
24
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
25
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
26
Ethanol Approved Phase 3 64-17-5 702
27
Phenol Approved, Experimental Phase 3 108-95-2 996
28 Cranberry Approved, Investigational Phase 3
29 Grape Approved Phase 3
30
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
31
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
32
Captopril Approved Phase 3 62571-86-2 44093
33
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
34
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
35
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
36
Cefazolin Approved Phase 3 25953-19-9 656510 33255
37
Ifosfamide Approved Phase 3 3778-73-2 3690
38
Etoposide Approved Phase 3 33419-42-0 36462
39
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
40
Daunorubicin Approved Phase 3 20830-81-3 30323
41
Tranexamic Acid Approved Phase 3 1197-18-8 5526
42
Zoledronic Acid Approved Phase 3 118072-93-8 68740
43
Molybdenum Approved Phase 3 7439-98-7 185498
44
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
45
Camptothecin Experimental Phase 3 7689-03-4
46
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
47 Fluorides Phase 3
48 Listerine Phase 3
49 Cariostatic Agents Phase 3
50 Endothelial Growth Factors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 230)
# Name Status NCT ID Phase Drugs
1 An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
2 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
3 Open-Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6 mg in Patients With Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, Within 7 Days After Initiation of Treatment Completed NCT02553707 Phase 4 Ibandronate
4 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
5 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
6 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
7 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
8 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
9 A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis Completed NCT01129336 Phase 4 Zoledronic acid;Standard Therapy
10 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
11 A Study to Determine Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Therapy of Metastases to Bone Completed NCT00688038 Phase 4
12 Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects Completed NCT01304121 Phase 4
13 A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride Recruiting NCT02312960 Phase 4
14 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
15 Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study Not yet recruiting NCT02480634 Phase 4 Zoledronic acid
16 A Randomized Placebo-Controlled Trial Of The Efficacy And Tolerability Of Flexibly Dosed Pregabalin In The Treatment Of Cancer-Induced Bone Pain Terminated NCT00381095 Phase 4 Pregabalin;Placebo
17 Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases: a Randomized Phase II/III Trial Unknown status NCT01429493 Phase 2, Phase 3
18 Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
19 18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques Unknown status NCT00882609 Phase 3
20 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
21 Randomized, Open Label Study to Evaluate Renal Safety of Intravenous Bondronat 6 mg Infusions Over 15 Minutes Versus 60 Minutes in Patients With Metastatic Bone Disease Due to Breast Cancer Completed NCT02716792 Phase 3 Ibandronate
22 Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer Completed NCT01419717 Phase 3 Denosumab
23 A Randomized, Double-blind, Multi-centre Study to Evaluate the Fficacy and Safety of Zometa as a Treatment in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma Completed NCT00219258 Phase 3 Zoledronic acid
24 Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies Completed NCT02561039 Phase 3 Ibandronate
25 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Completed NCT00330759 Phase 3 Zoledronic Acid
26 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer Completed NCT00321620 Phase 3 zoledronic acid
27 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer Completed NCT00321464 Phase 3 Zoledronic Acid
28 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma Completed NCT00950911 Phase 3 amg 162
29 Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases Completed NCT00524849 Phase 2, Phase 3 Zoledronic acid
30 Randomized Trial of Vertebroplasty and Radiotherapy Versus Radiotherapy Alone for Osseous Spine Metastases Completed NCT00267033 Phase 3
31 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma Completed NCT01345019 Phase 3 Denosumab;Zoledronic acid;Placebo to Denosumab;Placebo to zoledronic acid
32 A Randomized Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Completed NCT01248585 Phase 3 Dexamethasone;Placebo
33 Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis Completed NCT00610272 Phase 3
34 Phase III Study of Palliative Radiotherapy for Bone Metastases Comparing Single to Multiple Fractions. Completed NCT00858741 Phase 3
35 Dexamethasone for the Prevention of a Pain Flare After Palliative Radiotherapy for Painful Bone Metastases: a Multi-center Double-blind Placebo-controlled Randomized Study Completed NCT01669499 Phase 3 Dexamethasone acetate;Placebo
36 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial Recruiting NCT03295981 Phase 3 Zoledronic Acid
37 A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma Recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
38 Phase 3 Study Evaluating Fentanyl Transmucosal in the Prevention of Pain Induced by Mobilization During Radiotherapy in Patients With Bone Metastasis Recruiting NCT02426697 Phase 3 fentanyl transmucosal;Placebo
39 Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia Recruiting NCT03389724 Phase 3 Capoten®
40 Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements Active, not recruiting NCT01479283 Phase 3 24-Hour Prophylactic Cefazolin* Antibiotic Regimen;5-Days Prophylactic Cefazolin* Antibiotic Regimen
41 A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms Active, not recruiting NCT02163226 Phase 2, Phase 3
42 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
43 Postoperative Bleeding Prevention in Massive Bone Tumour Resection: a Multicentric, Randomized, Parallel, Controlled Trial to Assess the Efficacy of Tranexamic Acid Versus Evicel® and Usual Haemostasis Terminated NCT02153593 Phase 3 Tranexamic Acid;Fibrin glue
44 A Randomized, Placebo-controlled, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain Terminated NCT00099203 Phase 3 ibandronate [Bondronat];zoledronic acid
45 A Randomized, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain Terminated NCT00099177 Phase 3 ibandronate [Bondronat];zoledronic acid
46 A Cross-over Comparison of the Diagnostic Accuracy of Technetium (99mTc) Medronate Injection Prepared With 99mTc Derived From Neutron-activation Produced 99Mo Versus the Current Reference Standard of 99mTc Derived From Fission-produced 99Mo Terminated NCT03002454 Phase 3 99mTc MDP Injection:neutron-bombardment
47 A Prospective, Randomized Pilot Study of Enbrel VS Placebo in Patients Receiving Radiation Therapy to Combat Fatigue and Cachexia Terminated NCT00127387 Phase 2, Phase 3 Enbrel
48 Using Mesenchymal Stem Cells to Fill Bone Void Defects in Patients With Benign Bone Lesions Withdrawn NCT00851162 Phase 2, Phase 3
49 Primary Pain Palliation and Local Tumor Control in Bone Metastases Treated With Magnetic Resonance-guided Focused Ultrasound Unknown status NCT01693770 Phase 1, Phase 2
50 Concurrent Xeloda and Radiotherapy for Bone Metastases Unknown status NCT00192777 Phase 2 Xeloda

Search NIH Clinical Center for Bone Cancer

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ZOLEDRONIC
zoledronic acid

Cochrane evidence based reviews: bone neoplasms

Sources

Genetic Tests for Bone Cancer

About this section
Sources

Anatomical Context for Bone Cancer

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Bone Cancer:

19
Bone

MalaCards organs/tissues related to Bone Cancer:

40
Bone, Breast, Prostate, Lung, Spinal Cord, Thyroid, Dorsal Root Ganglion
Sources

Publications for Bone Cancer

About this section

Articles related to Bone Cancer:

(show top 50) (show all 1510)
# Title Authors PMID Year
1
The prognostic analysis of different metastatic patterns in pancreatic neuroendocrine tumors patients: A population based analysis. 42
31689842 2019
2
Incidence and prognosis of patients with spinal metastasis as the initial manifestation of malignancy: analysis of 338 patients undergoing surgical treatment. 42
31674246 2019
3
Parathyroid Hormone-Related Protein (PTHrP): An Emerging Target in Cancer Progression and Metastasis. 42
31576548 2019
4
Early urine proteome changes in an implanted bone cancer rat model. 61
31886325 2020
5
Endoplasmic Reticulum Stress Contributes to Nociception via Neuroinflammation in a Murine Bone Cancer Pain Model. 61
31939851 2020
6
Evidence of the involvement of spinal αB-crystallin in the maintenance of bone cancer pain in rats. 61
32016842 2020
7
Alantolactone suppresses human osteosarcoma through the PI3K/AKT signaling pathway. 61
31974628 2020
8
Gene Prioritization through Consensus Strategy, Enrichment Methodologies Analysis, and Networking for Osteosarcoma Pathogenesis. 61
32033398 2020
9
LncRNA DANCR silence inhibits SOX5-medicated progression and autophagy in osteosarcoma via regulating miR-216a-5p. 61
31918278 2020
10
Dual-targeting liposome modified by glutamic hexapeptide and folic acid for bone metastatic breast cancer. 61
32017901 2020
11
Renegotiation of identity in young adults with cancer: A longitudinal narrative study. 61
31841739 2020
12
Osteosarcoma growth suppression by riluzole delivery via iron oxide nanocage in nude mice. 61
31789402 2020
13
Delineation of hypoxia-induced proteome shifts in osteosarcoma cells with different metastatic propensities. 61
31959767 2020
14
Size-dependent apoptotic activity of gold nanoparticles on osteosarcoma cells correlated with SERS signal. 61
31931389 2020
15
Cold Plasma-Treated Ringer's Saline: A Weapon to Target Osteosarcoma. 61
31963398 2020
16
Comparison of Wide Margin and Inadequate Margin for Recurrence in Sacral Chordoma: A Meta-Analysis. 61
31977678 2020
17
Mesoporous Silica Nanoparticles for the Treatment of Complex Bone Diseases: Bone Cancer, Bone Infection and Osteoporosis. 61
31968690 2020
18
Basic fibroblast growth factor promotes doxorubicin resistance in chondrosarcoma cells by affecting XRCC5 expression. 61
31916307 2020
19
Tomatidine Represses Invasion and Migration of Human Osteosarcoma U2OS and HOS Cells by Suppression of Presenilin 1 and c-Raf-MEK-ERK Pathway. 61
31941156 2020
20
Green synthesized zinc oxide nanoparticles regulates the apoptotic expression in bone cancer cells MG-63 cells. 61
31770706 2020
21
Spinal circRNA-9119 Suppresses Nociception by Mediating the miR-26a-TLR3 Axis in a Bone Cancer Pain Mouse Model. 61
31368062 2020
22
Intrathecal administration of SRT1720 relieves bone cancer pain by inhibiting the CREB/CRTC1 signalling pathway. 61
31722235 2020
23
Trends of temporal bone cancer: SEER database. 61
31727339 2020
24
Bisphosphonates-much more than only drugs for bone diseases. 61
31705903 2020
25
SAP102 contributes to hyperalgesia formation in the cancer induced bone pain rat model by anchoring NMDA receptors. 61
31682872 2020
26
Novel Techniques to Study the Bone-Tumor Microenvironment. 61
32030644 2020
27
From Simple to Architecturally Complex Hydrogel Scaffolds for Cell and Tissue Engineering Applications: Opportunities Presented by Two-Photon Polymerization. 61
31746140 2020
28
Correction to: Spinal circRNA-9119 Suppresses Nociception by Mediating the miR-26a-TLR3 Axis in a Bone Cancer Pain Mouse Model. 61
31713153 2020
29
Endoplasmic Reticulum Stress Contributes to Nociception via Neuroinflammation in a Murine Bone Cancer Pain Model. 61
31841444 2019
30
Suppression of WNK1-SPAK/OSR1 Attenuates Bone Cancer Pain by Regulating NKCC1 and KCC2. 61
31085334 2019
31
Targeting MOR-mGluR5 heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5. 61
31271770 2019
32
Minocycline Relieves Depressive-Like Behaviors in Rats With Bone Cancer Pain by Inhibiting Microglia Activation in Hippocampus. 61
31743195 2019
33
History of Dose, Risk, and Compensation Assessments for US Veterans of the 1966 Plutonium Cleanup in Palomares, Spain. 61
31283545 2019
34
Cannabinoid receptor 2‑selective agonist JWH015 attenuates bone cancer pain through the amelioration of impaired autophagy flux induced by inflammatory mediators in the spinal cord. 61
31661120 2019
35
Modification of PMMA Cements for Cranioplasty with Bioactive Glass and Copper Doped Tricalcium Phosphate Particles. 61
31881672 2019
36
Medical infrared thermal imaging of canine appendicular bone neoplasia. 61
31796069 2019
37
Exploration of quinolone and quinoline derivatives as potential anticancer agents. 61
31410781 2019
38
A Novel Mechanism of BAM8-22 Inhibiting Microglia Activation: Represses CX3CR1 Expression via Upregulating miR-184. 61
31833017 2019
39
Super-paramagnetic nanostructured CuZnMg mixed spinel ferrite for bone tissue regeneration. 61
31546418 2019
40
Identification and validation of microRNAs and their targets expressed in osteosarcoma. 61
31656545 2019
41
Curcumin Releasing Eggshell Derived Carbonated Apatite Nanocarriers for Combined Anti-Cancer, Anti-Inflammatory and Bone Regenerative Therapy. 61
31039839 2019
42
Delays in the health care system for children, adolescents, and young adults with bone tumors in Brazil. 61
30075119 2019
43
The Ubiquitination of Spinal MrgC Alleviates Bone Cancer Pain and Reduces Intracellular Calcium Concentration in Spinal Neurons in Mice. 61
31515677 2019
44
Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer. 61
31567367 2019
45
AAV-mediated siRNA against TRPV1 reduces nociception in a rat model of bone cancer pain. 61
31296147 2019
46
SIRT1 Activation Attenuates Bone Cancer Pain by Inhibiting mGluR1/5. 61
31270711 2019
47
Tissue-engineered 3D models for elucidating primary and metastatic bone cancer progression. 61
31419564 2019
48
Production of reactive species in alginate hydrogels for cold atmospheric plasma-based therapies. 61
31695110 2019
49
Synthesis, characterization, kinetic drug release and anticancer activity of bisphosphonates multi-walled carbon nanotube conjugates. 61
31499981 2019
50
Fertility optimization in women with cancer: from preservation to contraception. 61
30969739 2019
Sources

Variations for Bone Cancer

About this section

Copy number variations for Bone Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 70082 12 58138784 58142025 Amplification SAS Bone cancer
2 70083 12 58141509 58146230 Amplification CDK4 Bone cancer
3 71134 12 67700000 68661632 Amplification MDM2 Bone cancer
Sources

Expression for Bone Cancer

About this section
Search GEO for disease gene expression data for Bone Cancer.
Sources

Pathways for Bone Cancer

About this section

Pathways related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Cytokine Signaling in Immune system 65
Show member pathways
 13.3 TP53 TNFSF11 TNFRSF11A MMP9 IL6 EGFR
2
Akt Signaling 63
Show member pathways
 13.3 TP53 TNFSF11 TNFRSF11A PENK IL6 EGFR
3
ERK Signaling 63
Show member pathways
 13.24 TP53 TNFSF11 TNFRSF11A PENK IL6 ESR1
4
PAK Pathway 63
Show member pathways
 13.23 TNFSF11 TNFRSF11A PENK IL6 EGFR CCL2
5
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.07 TP53 MMP9 IL6 EGFR CYCS CCL2
6
Phospholipase-C Pathway 63
Show member pathways
 13 TP53 PENK IL6 EGFR COL1A1 BMP2
7
G-Beta Gamma Signaling 63
Show member pathways
 12.95 RLN2 MMP9 EGFR CNR1 CDKN2A BMP2
8
Human cytomegalovirus infection 36
Show member pathways
 12.83 TP53 IL6 EGFR CYCS CDKN2A CCL2
9
Gastric cancer 36
Show member pathways
 12.71 TP53 TNFSF11 ESR1 EGFR CDKN2A
10
TNFR1 Pathway 63
Show member pathways
 12.59 TP53 TNFSF11 TNFRSF11A MMP9 IL6 EGFR
11
Relaxin signaling pathway 36
Show member pathways
 12.58 RLN2 MMP9 ESR1 EGFR COL1A1
12
Glioma 36
Show member pathways
 12.58 TP53 MMP9 ESR1 EGFR CDKN2A
13
Pathways in cancer 36
12.58 TP53 MMP9 IL6 ESR1 EGFR CYCS
14
Proteoglycans in cancer 36
12.18 TP53 MMP9 ESR1 EGFR COL1A1
15
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.14 TP53 PENK IL6 EGFR BMP2
16
Colorectal Cancer Metastasis 63
12.09 TP53 MMP9 IL6 EGFR
17
Interleukin-4 and 13 signaling 65
11.87 TP53 MMP9 IL6 CCL2
18
Rheumatoid arthritis 36
11.76 TNFSF11 TNFRSF11A IL6 CCL2
19
Senescence and Autophagy in Cancer 1
11.74 TP53 IL6 COL1A1 CDKN2A BMP2
20
Platinum drug resistance 36
11.69 TP53 CYCS CDKN2A
21
Microglia Activation During Neuroinflammation: Microglia Polarization 64
11.66 MMP9 IL6 CCL2
22
AGE/RAGE pathway 1
11.62 MMP9 EGFR CYCS
23
Bladder cancer 36 1
11.62 TP53 MMP9 EGFR CDKN2A
24
LPA receptor mediated events 1
11.61 MMP9 IL6 EGFR
25
Transcription_P53 signaling pathway 22
11.61 TP53 CDKN2A BMP2 ATF3
26
Lung fibrosis 1
11.59 MMP9 IL6 CCL2
27
Cell adhesion_ECM remodeling 22
11.56 MMP9 EGFR COL1A1
28
Photodynamic therapy-induced AP-1 survival signaling. 1
11.41 TP53 IL6 EGFR CDKN2A
29
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.32 TNFSF11 TNFRSF11A IL6 COL1A1
30
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.23 MMP9 IL6 CCL2
31
Spinal Cord Injury 1
11.18 TP53 PDYN MMP9 IL6 EGFR CCL2
32
G-protein signaling_Rap2B regulation pathway 22
10.88 TNFSF11 PENK IL6 EGFR COL1A1 CCL2
Sources

GO Terms for Bone Cancer

About this section

Cellular components related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.32 TNFSF11 RLN2 PENK PDYN MMP9 IL6

Biological processes related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.1 TP53 TNFSF11 IL6 ESR1 EGFR CDKN2A
2 positive regulation of transcription, DNA-templated GO:0045893 9.95 TP53 IL6 ESR1 EGFR COL1A1 CDKN2A
3 cytokine-mediated signaling pathway GO:0019221 9.93 TP53 TNFSF11 MMP9 IL6 CCL2
4 positive regulation of cell migration GO:0030335 9.92 MMP9 EGFR COL1A1 BMP2
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.83 TNFSF11 TNFRSF11A IL6 ESR1
6 response to estradiol GO:0032355 9.81 PENK ESR1 EGFR COL1A1
7 cellular response to growth factor stimulus GO:0071363 9.76 TRPV1 EGFR BMP2
8 positive regulation of epithelial to mesenchymal transition GO:0010718 9.74 IL6 COL1A1 BMP2
9 cellular response to reactive oxygen species GO:0034614 9.72 TP53 MMP9 EGFR
10 PERK-mediated unfolded protein response GO:0036499 9.63 CCL2 ATF3
11 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.62 TP53 ATF3
12 sensory perception of pain GO:0019233 9.62 TRPV1 PENK CNR1 CCL2
13 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.61 TP53 ESR1
14 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 TP53 EGFR
15 positive regulation of bone resorption GO:0045780 9.61 TNFSF11 TNFRSF11A EGFR
16 regulation of neuroinflammatory response GO:0150077 9.6 MMP9 IL6
17 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.59 TP53 ESR1
18 tooth eruption GO:0044691 9.58 TNFSF11 COL1A1
19 TNFSF11-mediated signaling pathway GO:0071847 9.56 TNFSF11 TNFRSF11A
20 monocyte chemotaxis GO:0002548 9.56 TNFSF11 TNFRSF11A IL6 CCL2
21 ossification GO:0001503 9.55 TNFSF11 TNFRSF11A EGFR COL1A1 BMP2
22 mammary gland alveolus development GO:0060749 9.54 TNFSF11 TNFRSF11A ESR1
23 positive regulation of apoptotic process GO:0043065 9.5 TRPV1 TP53 MMP9 IL6 CNR1 CDKN2A
24 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.48 TNFSF11 TNFRSF11A
25 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.46 TNFSF11 TNFRSF11A
26 positive regulation of gene expression GO:0010628 9.23 TP53 TNFSF11 RLN2 MIR140 IL6 CDKN2A

Molecular functions related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.62 TNFSF11 IL6 CCL2 BMP2
2 nitric-oxide synthase regulator activity GO:0030235 9.26 ESR1 EGFR
3 identical protein binding GO:0042802 9.23 TRPV1 TP53 TNFSF11 MMP9 ESR1 EGFR
4 opioid receptor binding GO:0031628 9.16 PENK PDYN
5 opioid peptide activity GO:0001515 8.96 PENK PDYN
Sources

Sources for Bone Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....